美第奇新星生物技術 MNOV 深 滬
等待開盤 06-25 09:30:00 美东时间
1.33
-0.030
-2.21%
華盛通- 最 高1.37
- 今 開1.36
- 成交量 2.86万股
- 最 低 1.3211
- 昨 收 1.36
- 總市值 6546.43万
- 52周最高 1.96
- 市盈率 靜 --
- 換手率 0.06%
- 52周最低 1.168
- 委 比 -32.75%
- 總股本 4922.12万
- 歷史最高 14.50
- 量 比 0.31
- 振 幅 3.60%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MediciNova Receives U.S. Patent Office Notice Of Allowance Covering The Use Of Ibudilast In The Treatment Of Glioblastoma
Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad range of treatment
06-08 20:07
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering the combination of ibudilast (MN-166) with an anti-PD-1 antibody for glioblastoma treatment. This patent, expected to expire in September 2042, strengthens the company's intellectual property for its combination therapy strategy. MN-166 is in late-stage development for neurodegenerative diseases and other conditions, wit...
06-08 12:00
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. has completed the last patient last visit (LPLV) in its Phase 2 clinical trial, MN-001-NATG-202, evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The study is a multicenter, randomized, double-blind, placebo-controlled trial comparing 500 mg/day of MN-001 to placebo over 24 weeks, with co-primary endpoints of liver fat co...
05-26 23:00
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
A study by CNIO researchers identifies MIF-mediated reprogramming of CD74-positive microglia and macrophages as a key vulnerability in brain metastasis. The research, published in *Cancer Research*, demonstrates that pharmacological modulation of this pathway using ibudilast (MN-166) can suppress metastasis. MediciNova plans to collaborate with CNIO on clinical trials for patients with brain metastases. The findings highlight a new therapeutic ap...
04-27 23:00
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $10
HC Wainwright & Co. analyst Lander Egaña Gorroño initiates coverage on MediciNova (NASDAQ:MNOV) with a Buy rating and announces Price Target of $10.
03-16 19:16
MediciNova to Participate at the 38th Annual ROTH Conference
<p>MediciNova, Inc. announced that its President and CEO, Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer, David H. Crean, Ph.D., will participate in the 38th Annual ROTH Conference on March 22-24, 2026, in Dana Point, CA. They will host investor meetings to provide company updates. The conference will include in-person one-on-one and small group meetings. More details are available at www.roth.com/conferences. MediciNova’s pipeline include...
03-16 11:00
MediciNova FY 2025 net sales hit USD 0.41M
MediciNova FY 2025 net sales hit USD 0.41M MNOV reported FY 2025 net sales of USD 409,657 (JPY 62.95 million) and an operating loss of USD 13.28 million (JPY 2.04 billion). Loss before income taxes was USD 11.99 million (JPY 1.84 billion), while net loss attributable to shareholders was USD 12 milli
02-20 19:25
美股大行评级 | 苹果、SanDisk、西部数据、卡特彼勒、德克斯户外、霍尼韦尔、西南航空、万事达等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Praxis Precision Medicine"买入"评级，目标价从340美元升至1245美元；HC Wainwright & Co.：维持Perspective Therapeutics"买入"评级，目标价从10美元升至12美元
02-02 14:15
D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target
D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:MNOV) with a Buy and maintains $9 price target.
01-30 20:50
